MorphoSys

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
星期三, 八月 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Operating cost, Ruxolitinib, SG, Tafasitamab, DLBCL, G&A, Patient, Administration, Research and development, R, Asset, Indolent lymphoma, Fine chemical, Cryptocurrency, Assurance services, Bookkeeping, Music, MorphoSys, Incyte

In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.

Key Points: 
  • In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.
  • Full Year 2023 Financial Guidance:
    100% of Monjuvi U.S. net product sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • Additional information related to 2023 Financial Guidance:
    Tremfya® royalties will continue to be recorded as revenue without any cost of sales in MorphoSys’ income statement.
  • MorphoSys Group Key Figures (IFRS, end of the second quarter: June 30, 2023)

EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
星期三, 八月 9, 2023
Rituximab, Ruxolitinib, MorphoSys, European Hematology Association, Conference call, Hydroxycarbamide, JAK, ICML, American Society of Clinical Oncology, Lymphoma, Lenalidomide, Cancer, FSE, Incyte, ASCO, BET, Publication, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, EHA, Annual general meeting, Webcast, Society, Conference, Safety, Nursing, Pharmaceutical industry, Beauty salon, Tafasitamab

Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.

Key Points: 
  • Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.
  • The MorphoSys AG Annual General Meeting on May 17, 2023 re-elected Mr. George Golumbeski, Ph.D., and Mr. Michael Brosnan to the Company’s Supervisory Board.
  • Events After the End of the Second Quarter of 2023:
    On August 1, 2023, Incyte announced the full enrollment of the Phase 3 study inMIND.
  • Total revenues for the second quarter 2023 were € 53.2 million compared to € 59.4 million for the same period in 2022.

EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Retrieved on: 
星期四, 八月 3, 2023
Webcast, Management, MorphoSys, FSE, Q&A, Conference, CEST, EDT, BST, Clothing, Video game

Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Key Points: 
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on August 10, 2023, at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the second quarter and first half 2023 and provide an outlook for 2023.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

Xencor Reports Second Quarter 2023 Financial Results

Retrieved on: 
星期四, 八月 3, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Janssen, G&A, Atopic dermatitis, CLDN6, European Society for Medical Oncology, Congress, Patient, Investment, STEAP1, R, NK, NMOSD, European Congress of Mathematics, Manuscript, Vir, EULAR, IND, Safety, CD3, Amgen, ESMO, Cancer, AMG, Antibody, Psoriasis, Ovarian cancer, Pembrolizumab, PARP, Renal cell carcinoma, Progression-free survival, CD28, Telephone, Part, Janssen Pharmaceuticals, Notifiable disease, Cytokine, Neuromyelitis optica spectrum disorder, European Society of Gynaecological Oncology, Tumor microenvironment, Vaccine, Pharmaceutical industry, Cryptocurrency, EU, Alexion, Ravulizumab, MorphoSys, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.
  • In the second quarter of 2023, Xencor earned $11.2 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Decreased net loss in the second quarter of 2023 compared to 2022 is primarily due to additional income and interest earned.
  • ET (1:30 p.m. PT) to discuss the second quarter 2023 financial results and provide a corporate update.

EQS-News: CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

Retrieved on: 
星期二, 六月 20, 2023
MorphoSys, CureVac, Messenger, Committee, Retirement, Supervisory board, CFO, CVAC, KPMG, Annual general meeting, Management

TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.

Key Points: 
  • TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.
  • Mr. Brosnan replaces Hans Christoph Tanner, who has been a member of CureVac’s Supervisory Board since 2015.
  • “Michael is an excellent addition to the CureVac board.
  • His global financial and audit experience will help manage financial stability as we move towards late-stage clinical development and commercialization,” said Jean Stéphenne, Chairman of CureVac’s Supervisory Board.

EQS-News: MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023

Retrieved on: 
星期四, 六月 15, 2023
Ruxolitinib, MorphoSys, Q&A, Joint Planning and Development Office, FSE, Mount Sinai, EDT, Assistant, Harvard Medical School, Patient, CEST, Webcast, Hospital, Massachusetts General Hospital, Cryptocurrency, Broadcasting, Medicine

MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023

Key Points: 
  • MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST.
  • During the event, Jean-Paul Kress, M.D., MorphoSys’ Chief Executive Officer, and Tim Demuth, M.D., Ph.D., MorphoSys’ Chief Research and Development Officer, will discuss the potential of the company’s lead investigational asset, pelabresib.
  • To access the live webcast, including audio, video and presentation slides, visit the Investors section of the MorphoSys website at https://www.morphosys.com/en/investors .

EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023

Retrieved on: 
星期三, 五月 17, 2023
Exercise, Islamabad Wildlife Management Board, Annual general meeting, MorphoSys, Annual, Mass meeting, FSE, Capital, Article, Conditional, Trust, Articles of association, CEST, Executive Committee, Supervisory board, Security (finance), Medical device

The ordinary Annual General Meeting 2023 was conducted without the physical presence of shareholders or their proxies, as permitted by German law.

Key Points: 
  • The ordinary Annual General Meeting 2023 was conducted without the physical presence of shareholders or their proxies, as permitted by German law.
  • Via a password-protected web service, registered shareholders could, among other things, submit questions, visually and audibly follow the entire Annual General Meeting and exercise their voting rights.
  • The terms of office of Supervisory Board members Dr. George Golumbeski and Mr. Michael Brosnan ended at the close of this Annual General Meeting on May 17, 2023.
  • They stood for re-election and were re-elected by the Annual General Meeting for a term of one year and three years, respectively.

Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

Retrieved on: 
星期二, 五月 16, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Fabry, Central nervous system, University, MorphoSys, Internal medicine, Head, China Executive Leadership Academy in Pudong, Drug, Patient, Molecular Partners, Novo Nordisk, Therapy, Pharmaceutical industry, Biopharmaceutical, Hematology, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.
  • “We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team,” said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo.
  • She has held several senior leadership positions in both clinical development and medical affairs in biotech and global pharmaceutical companies, having most recently served as Chief Medical Officer at Viracta Therapeutics.
  • Other previous roles include Chief Medical Officer at Molecular Partners, and VP, Head of Clinical Development at MorphoSys AG.

EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

Retrieved on: 
星期四, 五月 11, 2023
Ruxolitinib, Partnership, Peripheral T-cell lymphoma, MorphoSys, European Hematology Association, Primary myelofibrosis, Half-life, American Society of Clinical Oncology, Bone marrow, Lenalidomide, Joint Planning and Development Office, FSE, Immunotherapy, ASCO, BET, Pancreatic serous cystadenoma, Intolerance, Cancer, Patient, Lymphoma, EHA, Annual general meeting, EZH2, EZH1, Society, Disease, Pharmaceutical industry, Medical imaging, Tafasitamab, Hydroxycarbamide

“The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.

Key Points: 
  • “The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.
  • Monjuvi in combination with lenalidomide was investigated in the Phase 2 L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
  • The presentations on Monjuvi include:
    An e-publication at ASCO and EHA of a new five-year sub-group analysis from L-MIND.
  • At ASCO, preliminary results from the Phase 2 portion of the study evaluating tulmimetostat across multiple tumor types will be presented during a poster session.

Xencor Reports First Quarter 2023 Financial Results

Retrieved on: 
星期一, 五月 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICOS, AACR, CD28, European Alliance of Associations for Rheumatology, Cancer, ENPP3, American Association for Cancer Research, Janssen, TACSTD2, NMOSD, Research, CLDN6, Part, Genentech, Antibody, AstraZeneca, CEACAM5, ASCO, Congress, Patient, STEAP1, Ipilimumab, Colorectal cancer, Vir, EULAR, Cytokine, PD-1, Neuromyelitis optica spectrum disorder, Ovarian cancer, European Alliance, IND, Tumor microenvironment, Roche, Vaccine, Pharmaceutical industry, Cryptocurrency, Video game, EU, MorphoSys, Astellas Pharma, Rheumatology, Alexion, Ravulizumab

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
  • In the first quarter of 2023, Xencor earned $10.5 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022.
  • ET (1:30 p.m. PT) to discuss the first quarter 2023 financial results and provide a corporate update.